Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder

NCT01370733 · View on ClinicalTrials.gov ↗

Study Summary

This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder. This is a multicenter study in which subjects will be randomized to receive treatment 5 days per week for 6 weeks. Subjects who complete 6 weeks of double-blind treatment may be eligible to receive up to four weeks of open label sTMS therapy or antidepressant medications during the follow-up phase of the study. Follow-up evaluation visits will be conducted during those four weeks, with the frequency of the visits determined by the treatment choice during that timeframe.

Conditions Studied

Interventions

  • DEVICE SHAM
  • DEVICE NEST-1 (NeoSync EEG Synchronized TMS)

Study Locations (18)

California

  • UCLA Depression Research & Clinic Program — Los Angeles
  • UCSD Medical Center — San Diego
  • UCLA-Harbor — Torrance

North Carolina

  • Duke University Brain Stimulation and Neurophysiology Center — Durham
  • Wake Forest University Medical Center — Winston-Salem

Pennsylvania

  • University of Pennsylvania — Philadelphia
  • Mood Disorders Treatment Research Program University of Pittsburgh-Western Psychiatric Institute and Clinic — Pittsburgh

Texas

  • UT Southwestern Medical Center — Dallas
  • R/D Clinical Research — Lake Jackson

Connecticut

  • Hartford Hospital Institute of Living — Hartford

Illinois

  • TMS Specialists Chicago — Chicago

Maryland

  • Sheppard Pratt Health System — Baltimore

Missouri

  • Washington University School of Medicine — St Louis

Trial Details

FieldValue
Enrollment Target 202 participants
Start Date 2012-05
Est. Completion 2013-09
Phase Phase 3

Sponsor

Wave Neuroscience

36 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01370733

The ClinicalTrials.gov registry entry for NCT01370733 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wave Neuroscience, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions — of which SHAM is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01370733 reports 18 study locations spanning 13 distinct geographic areas — top geographies include California, North Carolina, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01370733 about?

NCT01370733 is a clinical study titled "Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder". This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder. This is a multicenter study in which subjects will be randomized to receive treatment 5...

What is the current status of trial NCT01370733?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2012-05. Estimated completion is 2013-09.

What conditions does trial NCT01370733 study?

This clinical trial studies the following conditions: Major Depressive Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01370733?

The interventions under investigation include: SHAM (DEVICE), NEST-1 (NeoSync EEG Synchronized TMS) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01370733?

This trial is sponsored by Wave Neuroscience, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01370733 being conducted?

This trial has 18 study locations across California, Connecticut, Illinois, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial